Rehmannioside A

CAS No. 81720-05-0

Rehmannioside A( —— )

Catalog No. M19140 CAS No. 81720-05-0

Rehmannioside A is an iridoid glucoside extracted from traditional Chinese medicine Rehmannia.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 171 In Stock
10MG 250 In Stock
25MG 422 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Rehmannioside A
  • Note
    Research use only, not for human use.
  • Brief Description
    Rehmannioside A is an iridoid glucoside extracted from traditional Chinese medicine Rehmannia.
  • Description
    Rehmannioside A is an iridoid glucoside extracted from traditional Chinese medicine Rehmannia.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    TNF
  • Recptor
    Others
  • Research Area
    Others-Field
  • Indication
    ——

Chemical Information

  • CAS Number
    81720-05-0
  • Formula Weight
    524.5
  • Molecular Formula
    C21H32O15
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C1=CO[C@H]([C@H]2[C@@H]1[C@@H]([C@H]1[C@@]2(O1)CO)O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO[C@@H]1[C@@H]([C@H]([C@H]([C@H](O1)CO)O)O)O)O)O)O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Liu C, et al. Rehmanniae Radix in osteoporosis: A review of traditional Chinese medicinal uses, phytochemistry, pharmacokinetics and pharmacology. J Ethnopharmacol. 2017 Feb 23;198:351-362.
molnova catalog
related products
  • Pomalidomide

    A potent inhibitor of TNF-α production; inhibits LPS-induced TNF-α release with IC50 of 13 nM in PBMCs.

  • Cucurbitacin IIA

    Cucurbitacin IIA can induce apoptosis and enhance autophagy, contributes to the anti-inflammatory activity of Cucurbitacin IIA against inflammation-related diseases.

  • Certolizumab pegol

    Certolizumab pegol (Certolizumab) is a polyethylene glycolated and humanized anti-TNF-α monoclonal antibody for the study of autoimmune diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA).